Washington, D.C., May 6, 2026. Generation Patient today published a new report, "Patent thickets increase costs and delay access to medicines for young adult patients," documenting how drug companies use terminal disclaimers to build patent thickets that delay generic competition and keep American drug prices high.

Last week, the House Subcommittee on Courts, Intellectual Property, Artificial Intelligence, and the Internet held an oversight hearing with U.S. Patent and Trademark Office (USPTO) Director John Squires. Chairman Darrell Issa (R-CA) raised several concerns about ongoing USPTO policies that are restricting public access to patent challenges. Generation Patient shares many of the concerns raised by Chairman Issa.

In October 2025, The United States Patent and Trade Office’s Patent Trial and Appeal Board (PTAB) recently proposed a rule that would change the institution of the Inter Partes Review (IPR) system, which is a system created to allow third party challenges to the validity of existing patents. Created under the Leahy-Smith America Invents Act (2011), or the AIA, the IPR system allows the general public to challenge the validity [...]

As a 21-year-old young adult patient living with several chronic and rare conditions, clinical trials have often felt like a double-edged sword. While they have the potential to bring new and effective treatments to the people that need them most, I find myself feeling frustrated because certain criteria often excludes me from applying to enter trials, one important factor being age.

The government has been shut down since October 1, 2025 due to the inability to come to a bipartisan consensus on how to continue funding the government through October 2025 and beyond. Due to this shutdown, social welfare programs that are controlled by the federal government are subject to delays or even complete closures which could impact benefits of millions of Americans, including young adults with chronic health conditions and/or [...]

During times of political disagreement, we stress the importance of bipartisanship to ensure the continued funding of the public programs that are so crucial in supporting young adults living with chronic and rare conditions in America. As patients, we rely on the continued operation of our Federal healthcare agencies to allow for the continued innovation and safety of therapeutics, the continued access to community health centers, the […]

GLP-1 agonist medications like Mounjaro, Wegovy, and Ozempic have exploded with popularity in the past few years. While these medications are not novel, they are now being used for more than type-2 diabetes management. Within the last five years, GLP-1s have gained FDA approval  for weight loss or obesity-management and obstructive sleep apnea, There are also studies into other possible uses for these medications, including for the treatment of […]

Earlier this week, FDA posted numerous warning letters and untitled letters to the manufacturers and telehealth companies for their marketing practices that are harming our young adult patient community. Among these companies targeted were those marketing unapproved compounded GLP-1s, with FDA labeling their products as misbranded. FDA also sent warning letters to manufacturers of approved GLP-1s who have been engaging in […]

Generation Patient welcomes today’s White House announcement of increased oversight and enforcement against deceptive direct-to-consumer (DTC) pharmaceutical advertising on social media platforms.

Have you noticed an increase in medication-related advertisements on your social media? Are the ads targeting your symptoms? Do you feel influenced to buy the medication online?